ILMN logoILMN
Illumina Inc

12,697
Loading...
Loading...
News
all
press releases
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
Zacks·6d ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·12d ago
News Placeholder
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·14d ago
News Placeholder
TMO Receives FDA Approval for Oncomine Dx Target Test
Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.
Zacks·1mo ago
News Placeholder
KMDA vs. ILMN: Which Stock Is the Better Value Option?
KMDA vs. ILMN: Which Stock Is the Better Value Option?
Zacks·1mo ago
News Placeholder
Illumina (ILMN) Reliance on International Sales: What Investors Need to Know
Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Zacks·1mo ago
News Placeholder
Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·2mo ago
News Placeholder
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +16.67% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech
Zacks·2mo ago
News Placeholder
Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Illumina (ILMN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Zacks·2mo ago

Latest ILMN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.